Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles by I. Malaty
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, I. Malaty wrote the following 2 articles about Parkinson Disease.
+ Citations + Abstracts
1 Article Health comorbidities and cognition in 1948 patients with idiopathic Parkinson's disease. 2012

Jones, J D / Malaty, I / Price, C C / Okun, M S / Bowers, D. ·Department of Clinical and Health Psychology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA. ·Parkinsonism Relat Disord · Pubmed #22776043.

ABSTRACT: BACKGROUND: Health comorbidities, particularly cardiovascular factors, are well known to pose risks for cognitive decline in older adults. This study examined the prevalence and contribution of comorbidities on cognitive performance in a large cohort of Parkinson patients. METHODS: Data on 1948 PD patients were obtained from the National Parkinson Foundation Quality Improvement Initiative (NPF-QII) registry, a multi-site initiative from NPF Centers of Excellence. Available comorbidity data included six common conditions (heart/circulation problems, diabetes, arthritis, cancer, respiratory disease, and other neurologic disease) that were clinician-rated for presence and severity. Available cognitive measures included semantic fluency and a 5-word recall memory task. The unique effects of comorbidities on cognition were analyzed (multiple hierarchical regression) controlling for demographic, PD disease severity (duration, Hoehn-Yahr), and medication status. RESULTS: The two most reported comorbidities were arthritis (46.6%) and heart/circulation problems (36.3%), with diabetes affecting 9% of the sample. Severity of heart/circulation problems independently contributed to worse delayed recall performance (p = 0.03). A trend emerged for more severe diabetes as contributing to worse semantic fluency scores (p = 0.06). CONCLUSIONS: This study with a large cohort of PD patients provides evidence for a small detrimental influence of specific health comorbidities, particularly heart/circulatory and diabetes, on general measures of cognition. This effect is present, above and beyond the influences of basic demographic information (age), duration and staging of PD, and medication status. Future studies involving more refined cognitive indices and direct assessment of comorbidities are warranted.

2 Article Usefulness of screening tools for predicting driving performance in people with Parkinson's disease. 2011

Classen, Sherrilene / Witter, D P / Lanford, D N / Okun, M S / Rodriguez, R L / Romrell, J / Malaty, I / Fernandez, H H. ·Institute for Mobility, Activity and Participation, University of Florida, PO Box 100164, Gainesville, FL 32611-0164, USA. sclassen@phhp.ufl.edu ·Am J Occup Ther · Pubmed #22026326.

ABSTRACT: OBJECTIVE: We used screening tests administered by a certified driving rehabilitation specialist and by Parkinson's disease (PD) specialty neurologists to develop a model to predict on-road outcomes for patients with PD. METHOD: We administered a battery of screening tests to 41 patients with PD and 41 age-matched control participants before on-road testing. We used statistical models to predict actual on-road performance. RESULTS: The PD group had a higher failure rate, indicating more on-road errors. For the PD participants, the Useful Field of View (UFOV) Subtest 2 and Rapid Pace Walk were responsible for most of the variance in the on-road test. The model accurately categorized pass-fail outcomes for 81% of PD patients. CONCLUSION: Clinical screening batteries may be predictive of driving performance in PD. The UFOV Subtest 2, administered in approximately 15 min, may be the single most useful clinical test for such predictions.